GlassScriptPhysician profile
Andres Tobon
NPI 1780799460
$11,541.16
in general payments reported to CMS, 2019-2025
37 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,710 · 2020: $2,133 · 2021: $777 · 2022: $982 · 2023: $508 · 2024: $973 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,840.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,142.01 | 2019-2024 | |
| Merz North America, INC. | $1,388.21 | 2019-2022 | |
| Journey Medical Corporation | $1,259.30 | 2019-2020 | |
| Janssen Biotech, INC. | $858.39 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $468.41 | 2024-2025 | Zoryve |
| Biofrontera INC. | $456.26 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $441.36 | 2019-2024 | Siliq |
| Abbvie INC. | $340.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $308.06 | 2019-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $305.18 | 2019-2025 | |
| Lilly USA, LLC | $292.94 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $184.12 | 2020-2021 | |
| Allergan, INC. | $177.42 | 2019-2022 | |
| Galderma Laboratories, L.P. | $175.33 | 2019-2025 | Nemluvio |
| Encore Dermatology INC. | $157.32 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $153.96 | 2019-2020 | |
| Genzyme Corporation | $150.87 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $146.84 | 2019-2020 | |
| Leo Pharma INC. | $143.31 | 2019-2025 | Adbry |
| Stemline Therapeutics INC. | $119.52 | 2021 | |
| Almirall LLC | $116.56 | 2019-2021 | |
| Ucb, INC. | $110.74 | 2021-2024 | Bimzelx |
| Janssen Scientific Affairs, LLC | $101.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $93.39 | 2019-2020 | |
| Genentech USA, INC. | $83.91 | 2019-2020 | |
| Amgen INC. | $80.57 | 2019-2022 | |
| Epi Health, LLC | $40.79 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $39.81 | 2019 | |
| Dermavant Sciences, INC. | $35.06 | 2022-2024 | Vtama |
| Merck Sharp & Dohme LLC | $31.56 | 2019 | |
| Organogenesis INC. | $25.14 | 2023 | Puraply |
| Incyte Corporation | $25.00 | 2023 | Opzelura |
| Mylan Pharmaceuticals INC. | $20.02 | 2019 | |
| Lnhc, INC | $19.18 | 2025 | Zelsuvmi |
| Taro Pharmaceuticals USA, INC. | $17.41 | 2019 | |
| Celgene Corporation | $17.06 | 2019 | |
| Dermira, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Tobon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.